Advanced Non Small Cell Lung Cancer clinical trials

Explore recruiting advanced non small cell lung cancer clinical trials.

Recruiting advanced non small cell lung cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Non Small Cell Lung Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib In Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

Poland, Spain, Portugal, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer

France, Spain, Italy, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)

Italy, Romania, Poland, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung)

Netherlands, Germany, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER

France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)

Italy, Spain, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Advanced Non Small Cell Lung Cancer trials by city

Advanced Non Small Cell Lung Cancer in Toronto Advanced Non Small Cell Lung Cancer in Vancouver Advanced Non Small Cell Lung Cancer in Montreal Advanced Non Small Cell Lung Cancer in Calgary Advanced Non Small Cell Lung Cancer in Edmonton Advanced Non Small Cell Lung Cancer in Ottawa Advanced Non Small Cell Lung Cancer in Winnipeg Advanced Non Small Cell Lung Cancer in Quebec City Advanced Non Small Cell Lung Cancer in Hamilton Advanced Non Small Cell Lung Cancer in Kitchener Advanced Non Small Cell Lung Cancer in London Advanced Non Small Cell Lung Cancer in Halifax Advanced Non Small Cell Lung Cancer in New York Advanced Non Small Cell Lung Cancer in Los Angeles Advanced Non Small Cell Lung Cancer in Chicago Advanced Non Small Cell Lung Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease